checkAd

    EQS-Adhoc  137  0 Kommentare Termination of the botulinum toxin project

    Für Sie zusammengefasst
    • Termination of botulinum toxin project.
    • Cooperation with Huons BioPharma ended.
    • No impact on company's operating business.

    EQS-Ad-hoc: HAEMATO AG / Key word(s): Strategic Company Decision
    Termination of the botulinum toxin project

    15-Nov-2023 / 19:42 CET/CEST
    Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.


    Berlin, 15. November 2023 – Due to new findings on changed market conditions, an updated validation of the profitability of the company's own botulinum toxin project was carried out.  After reviewing various options, the Executive Board decided today to terminate the cooperation with the Korean manufacturer Huons BioPharma and to discontinue the project for a proprietary botulinum toxin. This decision has no impact on the company's operating business.

    About HAEMATO:
    HAEMATO AG was founded in 1993 and is a pharmaceutical company with a focus on the trading of high-priced specialty pharmaceutical drugs (with a therapeutic emphasis on oncology, HIV, rheumatology and other chronic diseases) as well as the development and distribution of medical products and own brands, particularly in the area of "Lifestyle & Aesthetics". HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Further information can be found at https://haemato.de.



    Contact:
    HAEMATO AG, Investor Relations
    Telefon: +49 (0)30 897 30 86 70
    ir@haemato.ag


    End of Inside Information

    15-Nov-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.eqs-news.com


    Language: English
    Company: HAEMATO AG
    Lilienthalstraße 5c
    12529 Schönefeld
    Germany
    Phone: +49 (0)30 897 30 86 70
    Fax: +49 (0)30 897 30 86 79
    E-mail: ir@haemato.ag
    Internet: www.haemato.ag
    ISIN: DE000A289VV1
    WKN: A289VV
    Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange
    EQS News ID: 1774581

     
    End of Announcement EQS News Service

    1774581  15-Nov-2023 CET/CEST

    fncls.ssp?fn=show_t_gif&application_id=1774581&application_name=news&site_id=wallstreet

    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-Adhoc Termination of the botulinum toxin project EQS-Ad-hoc: HAEMATO AG / Key word(s): Strategic Company Decision Termination of the botulinum toxin project 15-Nov-2023 / 19:42 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by …

    Schreibe Deinen Kommentar

    Disclaimer